SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-311423
Filing Date
2013-07-31
Accepted
2013-07-31 07:08:59
Documents
11
Period of Report
2013-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d542774d10q.htm 10-Q 547014
2 EX-10.51 d542774dex1051.htm EX-10.51 37260
3 EX-31.1 d542774dex311.htm EX-31.1 9865
4 EX-31.2 d542774dex312.htm EX-31.2 9888
5 EX-32.1 d542774dex321.htm EX-32.1 5130
  Complete submission text file 0001193125-13-311423.txt   6424397

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT vnda-20130630.xml EX-101.INS 574432
7 XBRL TAXONOMY EXTENSION SCHEMA vnda-20130630.xsd EX-101.SCH 59482
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20130630_cal.xml EX-101.CAL 68731
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20130630_def.xml EX-101.DEF 298673
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20130630_lab.xml EX-101.LAB 394031
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20130630_pre.xml EX-101.PRE 363659
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 13997446
SIC: 2834 Pharmaceutical Preparations